Offering Clinically Proven, Regulatory Approved Cancer Tests for the $8 Billion Global In-Vitro Oncology Diagnostics Market

Radient PHARMACEUTICALS

OTCQX:RXPC

www.radient-pharma.com

CORPORATE HEADQUARTERS
2492 Walnut Ave. Suite #100
Tustin, California 92780
Tel: 714-505-4460

FINANCIAL SUMMARY (7/10/11)

Shares Outstanding:	174 M
Float:	174 M
Avg. Daily Trading :	3.3 M
Market Cap:	$20.99 M
Recent Price:	$0.13
Revenues FY 2010:	$231,662

IVD REGULATORY APPROVALS:

- US FDA Cleared as tumor marker for colorectal cancer monitoring of treatment and recurrence
- Canada's Health Canada cleared as tumor marker for lung cancer detection and monitoring of treatment and recurrence
- European Union's CE Mark as general cancer tumor marker; Cleared to market in 27 EU countries

EFFICACY IN DETECTING 15 CANCERS:

Colon; Rectal; Lung; Ovarian; Pancreatic; Breast; Stomach; Esophageal; Cervical; Throphoblast Thyroid; Malignant Lymphoma; Liver; Tongue; Brain

INVESTOR CONTACT:
Dilek Mir
T: 714-881-0244
E: dmir@radient-pharma.com

Company Overview

Radient Pharmaceuticals Corporation ("Radient") is dedicated to saving lives and money for patients and global healthcare systems through the deployment of its In Vitro Diagnostic Onko-Sure® cancer test. Clinical studies show Onko-Sure's® effectiveness in detecting 15 different types of cancer in early stages. Onko-Sure® has regulatory approval for specific indications in the US, Canada, the European Union, and numerous countries in Asia. The Company's focus is on the discovery, development and commercialization of unique high-value diagnostic tests that help physicians answer important clinical questions related to early disease state detection, treatment strategy, and the monitoring of disease progression or recurrence.

Investment Catalysts

Recent Focus on IVD Business: In fiscal 2010, Radient Pharmaceuticals transitioned from being a company whose primary source of revenues was derived from a China-based pharmaceutical manufacturing and marketing business, to its current business - the development and marketing of cancer in vitro diagnostics (IVD)s. With this recent transition, Radient is now focused on building long term sustainable revenues in the $8 billion global oncology IVD market (Source: Kalorama Information).

Multiple Revenue Stream Opportunities: Radient's platform technology is a cancer tumor marker offering a high sensitivity and specificity. It addresses the need for cancer detection and monitoring at the earlier stages of a tumor. There are numerous revenue opportunities for each cancer indication, nationally and globally. Additional revenue opportunities are also available in selling IVDs based on this proprietary platform technology for research use to oncology pharmaceutical developers and the large potential market in veterinary care.

Building Marketing & Distribution Channels for Approved Indications: Radient is currently pursuing the establishment and/or expansion of sales, marketing and distribution channels in each of the indications where it has regulatory approval: Onko-Sure® for the treatment and recurrence monitoring of colorectral cancer in the US; Onko-Sure® for detection and monitoring of lung cancer in Canada; Onko-Sure® as a general cancer tumor marker in Europe and parts of Asia.

Plan To Introduce IVDs for New Indications in US in Conjunction with CLIA Certified Labs: Radient intends to launch IVDs based on its platform technology in the US for new indications in conjunction with CLIA-certified labs. Under CLIA regulations, these labs may offer tests that are clinically proven to be effective. Radient intends to concurrently apply for FDA clearance for each new indication. The Company has a pipeline of indications for approval, backed by internal and external clinical data.

Intellectual Property Portfolio: Radient has been granted two patents by the US Patent and Trademark Office for its IVD cancer diagnostics. The Company has applied for and has two more patents pending that cover the most recent advancements in its technology.

Radient PHARMACEUTICALS

THE GLOBAL CANCER IN VITRO DIAGNOSTICS MARKET IS GROWING AT 11% PER YEAR.

2011: ESTIMATED $7.6 B MARKET
2014: PROJECTED $10 B MARKET
ACCORDING TO KALORAMA INFORMATION

MARKET OPPORUNITY

The global market for IVD cancer tests is growing at a rapid pace driven by several factors. IVDs are a useful tool in the early diagnosis of cancer, thus saving lives, reducing human suffering, and reducing healthcare costs. Recent scientific developments have enabled the discovery of a growing number of biomarkers associated with cancer, leading to new IVDs in the market. There is a growing demand for better healthcare in emerging growth economies across the world, including the "BRIC" countries (Brazil, Russia, India, and China) and other developing nations in Asia and South America. According to Kalorama Information, worldwide oncology IVD sales are estimated to be $7.6 billion this year and will reach $8 billion by 2012 and $10 billion by 2014.

INDUSTRY POSITIONING

Radient is an emerging player in the cancer IVD market. Having recently refocused its primary business onto the product that was developed through in-house research, Radient has significant market opportunities to pursue immediate sales with an IVD that already has regulatory approvals for several indications in various global markets. As the financial reporting environment for Chinese entities has proven to be challenging for US publicly listed companies, Radient divested of its Chinese subsidiary and focused on further development and commercialization of its Onko-Sure® IVD platform.

Currently, Radient's primary asset is the Onko-Sure® test, which is potentially one of the most robust solid cancer tumor markers available today. Having already invested in development and regulatory approval for one indication in the US and several other indications globally, the Company is in the fortunate position of building sales and distribution channels, establishing reimbursement, and building revenue momentum. The Company's prior investments in R&D, intellectual property, and regulatory approval provide strong barriers to entry. Once a cancer test emerges and establishes itself as the 'standard of care', this market acceptance typically provides further barriers to potential new competitors.

THE SCIENCE

Radient's platform IVD technology is a simple, non-invasive, cancer blood test kit which measures the accumulation of Fibrin and Fibrinogen Degradation Products (FDP) in serum. Blood is drawn from a patient, the serum is separated, and is applied to this kit. The kit process takes a couple of hours.

FDP levels rise dramatically with the progression of cancer. The production of FDP is restricted in healthy individuals. However, cancer cells release proteolytic enzymes as they grow and metastasize. Furthermore, cancer cells redirect the coagulation pathway. These events lead to overproduction of FDP in the process of carcinogenesis. DR-70® antigen is freely diffusible in blood and is therefore abundant and easy to be measured even in low concentrations at early stages of the cancer.

Radient PHARMACEUTICALS

Current assays (tests) for FDP only measure one out of many FDP components. In contrast, Radient's proprietary IVD detects the full array of FDP (breakdown products of fibrin and fibrinogen), which makes it a much more sensitive test. This test acts as a "barometer for cancer" by simultaneously measuring the multiple FDP species that may be underestimated by other tests. Because FDP is increased by any solid tumor, Radient's IVD test, which detects the complete array of FDP is a useful test to indicate the likelihood of the presence of a solid tumor anywhere in the body. For this reason, it is suited as a general cancer detection test. Considering the patients' detailed history and when this IVD is coupled with other tumor markers, or imaging techniques such as x-ray or MRI scans, this combination becomes a very powerful tool in detecting tumors, identifying the exact location of a tumor and monitor the treatment or post-treatment recurrence.

Clinical data supports the medical utility of Radient's proprietary IVD in detecting and monitoring 15 different cancers. Additional clinical data shows that FDP is present in 19 different cancers, thereby indicating that the test may be effective in detecting and/or treatment/recurrence monitoring for 19 cancer types. There are a total of 58 published studies in peer-reviewed journals, with 15 specific to Radient's IVD and the rest regarding FDP products and cancer. The following table outlines results of clinical data published in peer-reviewed journals.

Effectiveness of Radient's IVD in Different Cancer Types

Type of Cancer	Effectiveness		No. of Studies
	Sensitivity (%)	Specificity (%)	
Colon/Rectal Cancer	54-87	67-99	7
Liver Cancer	50-100	70-95	5
Lung Cancer	66-100	92-95	4
Ovarian Cancer	57-86	57-100	4
Pancreatic Cancer	65-92	67-95	4
Stomach Cancer	80-100	70-95	4
Breast Cancer	65-73	70-95	3
Esophaegial Cancer	100	95	2
Lymphoma	100	95	2
Tongue Cancer	73	93	1
Brain Cancer	100	95	1
Thyroid Cancer	75	70	1

Radient has ongoing R&D and clinical trials for indications in which its IVD has already proven effective in independent clinical trials. As trials are concluded, Radient's scientists, in conjunction with external collaborators, intend to publish results in peer reviewed journals. The Company intends to expand the body of research on its portfolio of proprietary IVD technologies.

A LARGE BODY OF CLINICAL DATA, PRIMARILY FROM INDEPENDENT STUDIES THROUGHOUT THE WORLD, PUBLISHED IN PEER REVIEWED PUBLICATIONS PROVE THAT RADIENT'S IVD WORKS

PRODUCTS & MARKETS

The Product: IVD Test Kits

Radient sells IVD test kits to labs in the form of a 96-well plate along with reagents. It is a standard sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA). For each kit, 5 standards and 2 controls use 14 of the 96 wells. After accounting for these standards and controls, 41 individual tests can be run simultaneously in duplicate and are typically run in a reference laboratory. Results are sent to an attending physician, who then relays the test results to the patient. In general, it takes 3-5 days from the blood draw date to receive the results. Radient does not process individual tests, rather it markets and sells the actual test kits that can be used to test 41 patients. The Company works through distributors that are either clinical reference labs or CLIA certified labs that market the test, draw the blood samples, processes the test, and send results to the attending physician.

Specific Indicated Uses in Various Markets

Radient's IVD technology targets numerous market segments within the $8 billion global cancer IVD market. The following is an outline of the current and future potential markets for the test kits.

Onko-Sure® for colorectal cancer: US Market

For Colorectal Cancer ("CRC") patients undergoing treatment, effective monitoring of the treatment strategy is the key for higher survival rate. Likewise, for colorectal cancer survivors (post-treatment), effective monitoring for disease recurrence is the most important part of an effective post-treatment follow-up plan. Onko-Sure® is the second monitoring test approved by the US FDA for the monitoring of CRC in over the past 25 years. The current standard of care for colorectal cancer patients during the treatment and post-treatment periods is to test for Carcinoembryonic Antigen (CEA) values. CEA is a tumor marker and is a standard blood test similar in platform to Onko-Sure®. Doctors typically monitor a CRC patient, post-surgery, by performing 12-15 CEA tests in the 2-5 years following surgery. In most cases of colorectal cancer recurrence more than 50% of the biopsy positive patients have negative Carcinoembryonic Antigen (CEA) values and are unable to be monitored with standard CEA test. In these cases, Onko-Sure® is a more valuable test for these patients with low CEA values. Combining CEA and Onko-Sure® generates a more accurate estimate of post-treatment CRC recurrence. When Onko-Sure® is used in conjunction with CEA, sensitivity rate increases by up to 20%, particularly in Stage I and Stage II patients. This means that the addition of Onko-Sure® helps to catch CRC recurrence in an earlier, greatly improving patient outcomes and survival rate.

According to the National Cancer Institute, in 2010, 142,570 people in US were diagnosed with colorectal cancer and 51,370 people died of the disease. Anything that can improve the survival rate of patients is important. Onko-Sure® which increases sensitivity by 20% offers a significant improvement.

Radient PHARMACEUTICALS

APPROVAL FOR NUMEROUS INDICATIONS, ACROSS SEVERAL GLOBAL GEOGRAPHICS MARKETS CREATE TREMENDOUS OPPORTUNITIES FOR COMMERCIALIZATION OF RADIENT'S IVD CANCER DIAGNOSTICS

Onko-Sure® is an immediate market opportunity for Radient. The product holds great promise for the US healthcare system to improve patients' well-being and survival rate as well as to reduce healthcare costs through better monitoring of treatment and an earlier diagnosis of recurrence. Radient has to date only offered Onko-Sure® on a limited basis and is now working on developing a larger-scale national distribution network of clinical reference labs to offer this test. Along with building such a distribution network, Radient also intends to continue to raise awareness of Onko-Sure® with doctors and patients. The Company regularly participates in different national and international scientific conferences as well as CRC patient advocacy group events in support of this goal.

Onko-Sure® for Lung Cancer: Canadian Market

Onko-Sure® has been approved for the detection and monitoring of lung cancer treatment and recurrence by Health Canada, the Canadian equivalent of the US FDA. Radient is currently evaluating potential distributors in the Canadian market and aims for a full launch in the Canadian market. The Company is also exploring support from the public payer market in Canada, as a majority of Canadians are covered by their national health plan. The Canadian National Health Plan must approve of funding a test, in addition to the regulatory approval for the efficacy of the test, which Radient has already received. This is an immediate market opportunity for Radient.

According to the Canadian Cancer Society, lung cancer is by far the leading cause of cancer death for both men and women. In 2011, an estimated 25,300 Canadians will be diagnosed with lung cancer and 20,600 will die of the disease.

Onko-Sure® (General Tumor Marker): Europe, Asia, International

Onko-Sure® is approved for sales as a general tumor marker in seven markets including the European Union, Asia and other markets. The Company currently has distributors in 15 markets; however, numerous current distributors have not met their minimum purchase requirements. The Company is now in the process of re-evaluating distributors and intends to pursue new distributorships with companies that are properly positioned and funded to launch and sell Onko-Sure® on a wide scale in their respective markets. International sales of this kit as a general cancer tumor marker is an immediate significant market and a significant revenue opportunity for Radient.

Lung Cancer IVD for US Market

There is strong, independent clinical data further validating Radient's IVD technology for the early detection of lung cancer. Particularly when used in combination with other tests and imaging techniques, the lung cancer IVD is a very useful tool in the early detection of lung cancer. In the US market, certain labs that are qualified to receive Clinical Laboratory Improvement Amendments (CLIA) status, have regulatory approval to offer tests that may not be FDA cleared, yet. Radient is currently evaluating potential CLIA lab partners to validate its lung cancer IVD internally at their labs and offer it to doctors and patients. Offering its lung cancer IVD through a CLIA lab may get this valuable diagnostic tool into the hands of doctors and patients immediately, while Radient continues to complete its clinical protocols for FDA clearance for the specific indication of this test in the detection and monitoring of lung cancer treatment and recurrence. Sales through CLIA labs is a relatively short term opportunity for Radient.

According to the US Centers for Disease Control, in 2007, 203,000 people in the US were diagnosed with lung cancer and 159,000 people in the US died of the disease. Globally, 1.4 million died of lung cancer according to the World Health Organization.

Radient PHARMACEUTICALS

SIGNIFICANT POTENTIAL FOR ONKO-SURE® SALES TO TWO NEW MARKETS:

- RESEARCH USE FOR CLINICAL TRIALS OF CANCER DRUGS
- DIAGNOSTICS FOR THE VETERINARY CARE MARKET

Ovarian Cancer IVD for US Market

Ovarian cancer is known as the silent killer. According to the National Cancer Institute, 21,880 women in the US were diagnosed with ovarian cancer in 2010 and 13,850 died of the disease that year. The incidence rate is relatively low, yet it is typically diagnosed late and therefore survival rates are dismal. CA-125 has been a well established tumor marker for ovarian cancer, yet it is not highly accurate. One other blood test for ovarian cancer has recently received FDA approval. Four independent clinical trials have been conducted on Radient's proprietary IVD's efficacy in early detection of ovarian cancer. Radient intends to work with CLIA lab partners who may validate its ovarian cancer IVD internally at their labs and offer it to doctors and patients. Offering its ovarian cancer IVD through a CLIA lab may get this valuable diagnostic tool into the hands of doctors and patients in the short term, while Radient continues to build its clinical protocols for eventual FDA clearance for the indication of detection and monitoring of ovarian cancer. This is a medium term opportunity for Radient.

Pancreatic Cancer IVD for US Market

Pancreatic cancer is one of the most lethal cancers, as diagnosis typically happens in later stages and survival rates are very low. The National Cancer Institute estimates 43,140 people were diagnosed with pancreatic cancer in the US in 2010 and 36,800 people died of the disease that year. Similar to its strategy for lung cancer and ovarian cancer indications in the US, Radient intends to work in collaboration with CLIA lab partners to validate its IVD technology internally at their labs and offer it to doctors and patients. This is a medium term opportunity for Radient.

Oncology IVD For Research Use For Pharmaceutical Developers

Numerous pharmaceutical developers including 'big pharma' and other smaller biotechs are conducting clinical trials on cancer drugs currently under development. Using diagnostics to monitor the effectiveness of therapeutics is a standard part of conducting clinical trials.

Radient has an immediate opportunity to sell its IVDs into the market for research use. Funded clinical trials budget for diagnostics and therefore this market is a 'cash' market which does not involve insurers or reimbursement coding. When diagnostics are used 'for research use only', in a research setting, FDA approval of the diagnostic is not a necessity. Thus, any cancer trial, may use Radient's IVD as a monitoring tool.

According to Salisonline.org, clinical trial spending in 2010 is an estimated $25 billion and is expected to reach $28.5 billion by 2014. In 2010, the total number of clinical trials in the U.S. is 25,992. This number is expected to increase at a 5.7% compound annual growth rate (CAGR) to reach 32,318 in 2014. Cancer patients in clinical trials are typically tested at least three times per year with diagnostics tools during the course of the treatment.

Cancer Diagnostics for Veterinary Use

Radient intends to further develop its platform technology for the veterinary market. The Company intends to initiate a clinical trial on the use of its cancer test platform for dogs and cats. Should the Company's clinical results prove promising, this opens a new and attractive ancillary market for Radient.

In 2004, according to the book, Veterinary Hematology and Clinical Chemistry, the most recent year for which published data is available, the global market for veterinary diagnostics was $600 million. A report by Gabelli & Company states that in the US alone, the market for veterinary drugs, lab services, and medical supplies was $2.5 billion in 2004. This is

primarily a cash market, however, an estimated 1 million companion animal owners have health insurance for their pets. This is a medium term opportunity for Radient, yet if clinical trial results prove effective, Radient may pursue this market in the nearer term.

RADIENT TO MAKE THE CASE TO INSURERS THAT ONKO-SURE® WILL NOT ONLY SAVE LIVES AND REDUCE HUMAN SUFFERING, BUT ALSO REDUCE LONG TERM HEALTHCARE COSTS FOR INSURERS, BOTH PUBLIC AND PRIVATE

HEALTHCARE ECONOMICS

The economics of healthcare is complex, driven by public payers such as Medicare in the US, and a host of private insurers offering HMOs, PPOs, and other varieties of insurance. Companies offering healthcare solutions including diagnostics, establish reimbursement procedures and codes to ensure their products will be covered by insurance. Newly introduced products typically require time for market adoption due to several reasons including the fact that insurers choose to reimburse products, or not, based upon their own internal policies and economics. Diagnostics providers must make the case to insurers that their products are effective, will improve patient care, and thereby reduce long term costs for insurers. Reimbursement may be established by either using pre-existing CPT codes (billing codes), or by applying for a new code for a new product. Currently there is no specific CPT code for Onko-Sure®. Radient is currently working on establishing appropriate reimbursement for its products.

Globally, healthcare economics and reimbursement vary widely across all markets and nations. Radient works closely with its distributors on payment strategies. Many emerging markets are 'concierge' markets where patients pay out of pocket for diagnostics.

FINANCIALS

Fiscal 2010 Results

For the fiscal year ended December 31, 2010, Radient reported net revenues were up approximately 47% to approximately $232,000 from approximately $158,000 in the prior fiscal year. Revenues were generated from sales of the Company's Onko-Sure® cancer test kit. Gross profit rose approximately 54% on increased sales volume in the fiscal year ended December 31, 2010 to approximately $185,000, from approximately $120,000 in fiscal 2009. Gross margins increased slightly on higher sales volumes to 80% in fiscal 2010, as compared to 76% in the prior fiscal year. These results do not include operations of JPI, the company's China-based pharmaceutical operations, which were deconsolidated in 2010.

Loss from operations for the year ended December 31, 2010 was approximately $14.1 million, as compared to loss from operations in the prior year of approximately $6.99 million. Approximately $3.7 million, or 26% of the fiscal 2010 loss from operations was due to a combination of a $2.6 million write-off of JPI, the Company's China subsidiary's receivable, and a $1.1 million impairment of the CIT patent technology asset.

Net loss for fiscal 2010 was approximately $85.7 million or a loss of $2.88 per share. Items comprising net loss included: 1) interest expense of approximately $38.5 million; 2) change in fair value of derivative liabilities of approximately $9.4 million; 3) impairment of investment in JPI of approximately $20.5 million; 4) loss on extinguishment of debt of approximately $3.2 million. Net loss for the prior fiscal year (exclusive of JPI), ended December 31, 2009 was approximately $11.1 million.

Radient PHARMACEUTICALS

MANAGEMENT TEAM BRINGS EXPERTISE IN BUILDING BUSINESS, IN ONCOLOGY, IN SCIENCE, AND IN MARKETING AND SALES

Fiscal 2011 Q1 Results

Revenue for the fiscal 2011 first quarter ended March 31, 2011 was approximately $31,000, as compared to approximately $37,000 in the period ended March 31, 2010. This decrease of 17% was due to a slight decrease in orders for the Onko-Sure® test kits during the quarter. RPC had an additional $28,700 in orders on-hand as of March 31, 2011, which were not shipped until April 2011. RPC therefore did not recognize such revenue until shipment was made in the second quarter.

Loss from operations for the three months ended March 31, 2011 was approximately $1.9 million, as compared to loss from operations for the comparable period in the prior year of approximately $1.4 million. The approximate $497,000 or approximate 36% increase in loss from operations was primarily due to an increase in selling, general and administrative expenses.

Net loss for the first quarter of fiscal 2011 was approximately $11.4 million or approximately a loss of $0.13 per share, as compared to first quarter fiscal 2010 net loss of approximately $2.6 million or a net loss of $0.11 per share. The increase in net loss is attributed to higher interest expense and a loss on extinguishment of debt, partially offset by a change in fair value of derivative liabilities.

Recent Debt Conversions & Financings

Having recently divested itself of Chinese pharmaceutical business, Radient has gone through financial restructuring, fund raising, retirement of debt, and conversation of debt to equity. As of July 8, 2011 the Company currently has approximately 177 million shares outstanding with 200 million authorized and approximately 110.2 million warrants and options are outstanding as of July 8, 2011. From December 2010 through the end of June 2011, approximately $27.6 million in corporate debt, including principal and interest was converted into equity. The Company raised approximately $8.4 million, with approximately $6.8 million in net proceeds through the issuance of convertible notes and warrants in the first quarter of 2011. These “2011 Notes” were exchanged in July of 2011 for 4% convertible notes in the aggregate principal amount of $4.95 million; and $6.701 million of 4% Series A convertible preferred stock. These new notes and preferred stock convert into the Company’s shares in four equal installments commencing August 1, 2011. The Company also issued the note holders approximately 94.5 million warrants priced at $0.185 per share. Radient shall seek shareholder approval to increase the number of authorized shares to 750 million shares of common stock.

Future Funding Needs

Until the Company can generate sufficient cash flow from sales of its Onko-Sure® cancer IVD tests, Radient will likely need to raise additional funds. The Company anticipates doing so through preferred equity financings. The Company’s aim is to achieve cash-flow positive and profitability through sales for indications for which Onko-Sure® is regulatory approved. Targeting an estimated $8 billion global market with products that already have regulatory approval, Radient is focused on successful commercialization to drive revenues and cash flow.

MANAGEMENT

Douglas MacLellan

Executive Chairman of the Board & Chief Executive Officer

With more than 25 years of international business management and active board experience, Mr. MacLellan has been a catalyst for the development, growth and success of many public and privately-held businesses worldwide. Throughout

his professional career, Mr. MacLellan has served on the board of 18 separate companies where he has played an instrumental role in strategic planning, general operations, corporate finance activities, economic policy, asset allocation and mergers & acquisitions. In addition, he has supported the raise of over US $715 million in capital financing for development early-stage, start-up and mid-cap companies. MacLellan received advanced training in classical economic theory and international relations from the University of Southern California and was a student of Arthur Laffer, Ph.D., who later employed him as an economist. Mr. MacLellan has also authored numerous industry-specific research papers and portfolio strategy and economic forecasts over the past 25 years.

Akio Ariura
Chief Operating Officer & Chief Financial Officer

Mr. Ariura's experience spans over 30 years in both private and publicly-held companies across various industries. As COO & CFO of Radient Pharmaceuticals, Mr. Ariura has worldwide responsibility for Radient's business operations and finances, including special projects such as Sarbanes-Oxley Compliance, U.S. Securities & Exchange Commission filings, and project management of mergers and acquisitions. Prior to joining Radient Pharmaceuticals, Mr. Ariura was Vice President, Sunvest Industries, LLC, in Lake Forest, California, where he oversaw the review, development and implementation of yearly budgets and developed internal controls for the company's operating manufacturing entities. Mr. Ariura also served as Chief Financial Officer for United States operations for Derlan Industries, a Canadian manufacturer with subsidiaries in the U.S. Mr. Ariura holds a B.S. degree in Business Administration from the University of Southern California.

Dr. Afsaneh Motamed-Khorasani
Director of Oncology

Dr. Motamed-Khorasani has a tenured and diverse range of experience in medical communication/affairs, basic and industrial research and development, clinical trials and intellectual property. Prior to joining RPC, Dr. Motamed-Khorasani served as a senior scientist and senior medical analyst at Amgen Inc., Microbix Biosystems Inc., Samuel Lunenfeld Research Institute at Mount Sinai Hospital, Princess Margaret Hospital and Vancouver General Hospital. She has more than 15 years experience and national certificates in GLP, GMP, ICH-GCP and FDA regulatory compliance for clinical trials and is a member of professional associations that include the Endocrine Society, American Association of Cancer Research (AACR), Iranian-American Medical Association (IAMA), Bitech and Pharma Professionals Network (BPPN), American Medical Writers Association (AMWA) and Intellectual Property Institute of Canada (IPIC). Dr. Motamed-Khorasani's research has focused on high throughput approaches in the context of cancer informatics with a particular interest in the use of comparative analysis for the mining of integrated oncology datasets that include protein-protein interaction and gene expression profiling. She has published and presented more than 35 peer-reviewed papers, abstracts, and articles in highly regarded scientific journals, and presented at many high profile conferences and scientific meetings. Of particular note, Dr. Motamed-Khorasani has offered significant contribution in the field of ovarian cancer when she highlighted two genes that may be involved in the prognosis of ovarian cancer. The results of this finding are published in the 2006 edition of the Oncogene Scientific Journal. Dr. Motamed-Khorasani received her PhD degree in Reproductive Endocrinology with a focus on epithelial ovarian cancer from the University of Toronto, Canada.

Mr. Christopher Gee
Director, International Sales & Marketing

Mr. Gee is a technology and biotech industry veteran with extensive international sales, marketing, and distribution management experience. Since 2004 he has held executive positions and managed projects in the US, China, Hong Kong,

Vietnam, and Taiwan including product development, marketing, sales, and distribution partnership planning. His responsibilities have spanned US and Asian business operations and included negotiated agreements with top tier international distribution companies. Mr. Gee's background includes three years as a senior analyst at New York University, Stern School of Business. He has also served as principal in several start-up companies. At Apple Inc. he successfully managed business development and enterprise computing projects. Mr. Gee received his MA from King's College, University of London and his BA from New York University.

Ms. Dilek Mir
Director, Business Development & Investor Relations
Ms. Mir has been an investor relations professional for 13 years, a founder of successful start-up companies, as well as having engaged in technology transfer in both the healthcare and high-tech fields. As an executive at Los Angeles and New York based investor relations agencies, she has advised and represented dozens of publicly traded technology and healthcare companies. Healthcare clients have included leaders in their product categories, as well as emerging companies subsequently sold to global healthcare giants. As an entrepreneur she is founder of ProteaSure, developer of a proteomic in-vitro diagnostic for endometrial cancer. Prior, she had founded, built and sold Polyglot International, the first privately owned language training firm in Moscow, which served over a dozen Fortune 500 clients. Ms. Mir sold Polyglot to Nord Anglia PLC, a global leader in private education. Ms. Mir received her Bachelor of Science in Finance and Political Science from the University of Massachusetts and her M.B.A. from Babson College in Wellesley, Massachusetts.

BOARD MEMBERS

Douglas MacLellan
Executive Chairman of the Board & Chief Executive Officer
See bio in management section.

Dr. Robert Beart Jr.
Independent Director
Dr. Beart, MD is currently the medical director of the Glendale Hospital Colorectal Cancer Institute. Previously he had been with the University of Southern California (USC) since 1992, establishing the Division of Colorectal Surgery in the USC Department of Surgery as well as launching the USC Center for Colorectal Diseases at USC University Hospital and USC/Norris Cancer Center and Hospital. Dr. Beart is a recognized specialist and expert in colorectal diseases and cancer, pioneer of the ileal pouch-anal anastomosis, and thought leader in the medical, scientific and research communities. From 1976 through 1992 Dr. Beart worked at the Mayo Clinic in Rochester, Minnesota where he was Chairman of Department of Colorectal Surgery and pioneered the ileal pouch-anal anastomosis. He is a past president of the American Society of Colon and Rectal Surgeons, the Society of Surgery of the Alimentary Tract and the International Society of University Colorectal Surgeons. He had his surgical training at the University of Colorado and the Mayo Clinic. Dr. Beart graduated from Harvard Medical School in 1971 and is board-certified and recertified in General and Colorectal Surgery.

Mr. Michael Boswell
Independent Director & Chairman of Audit & Compensation Committees
Mr. Boswell is a co-founder of the TriPoint family of companies and co-founder and member of TriPoint Capital Advisors, LLC, a boutique merchant bank focused on small and mid-sized growth companies and co-founder, President and COO of TriPoint Global Equities, LCC, a FINRA member firm. Mr. Boswell provides high-level financial services and executive guidance to start-up businesses and small to mid-sized companies. He is a recognized expert in corporate finance, structure and governance; mergers and acquisitions; SOX 404 compliance; SEC rules, reporting and disclosure; FASB

Emerging Issues Task Force issues specifically as they relate to private placements; employee option programs; and the reverse merger strategy and process. Prior to co-founding the TriPoint family of companies, Mr. Boswell held various executive positions with business development and management consulting firms. Mr. Boswell holds the Series 24, 62, 82 and 63 licenses with TriPoint Global Equities. Mr. Boswell also spent eight years as a senior analyst and senior engineer in various branches of the United States Government. He earned a MBA from John Hopkins University and a BS degree in Mechanical Engineering from University of Maryland.

Dr. Robert L. Rooks DVM, MS
Independent Director

Dr. Rooks DVM, MS is a thought leader in the veterinary care market. He is an author, award-winning practicing veterinarian, and founder and retired director of VCA All-Care Animal Referral Center. Under his leadership, his VCA practice has grown into an organization comprised of three subsidiaries that include the All-Care Animal Referral Center, the Animal Orthopedic Care Center, and the Animal Cancer Care Center. Collectively, these centers are staffed by more than 25 veterinarians and 65 technicians who see over 30,000 patient cases annually under Dr. Rooks' guidance. In addition to his corporate endeavors, Dr. Rooks is very active in the veterinarian community, providing state-of-the-art continuing education programs for technicians and veterinarians in Southern California. As a part of this work, Dr. Rooks initiated a publication called ARCives which is distributed to technicians and veterinarians who refer clients and patients to All-Care Animal Referral Center. Dr. Rooks and All-Care Animal Referral Center have been featured in recent years in *Money* and *Forbes* magazines. Dr. Rooks has appeared on CBS This Morning and the Australian TV show *"Talk to the Animals, Advances in Veterinary Medicine"* and the Agriculture USA television program entitled *"The Cutting Edge of Veterinary Medicine"* which was filmed in his hospital. Dr. Rooks is a 1978 graduate of Iowa State University and a Diplomate of both the American Board of Veterinary Practitioners and the American College of Veterinary Surgeons. Dr. Rooks developed a surgical procedure and specialized implant for the treatment for hip dysplasia in dogs and is co-author of *Canine Orthopedic* and the *Veterinary Cancer Therapy Handbook: Chemotherapy, Radiation Therapy, and Surgical Oncology for the Practicing Veterinarian*. He is the past president of the Orange County Chapter of The Southern California Veterinary Medical Association and of the Animal Health Foundation and recipient of the Iowa State University Outstanding Young Alumnus Award, AAHA EXCEL Award, and highly prestigious Charles E. Bild Practitioner of the Year Award.

Mr. Henry Jia
Director

Mr. Jia has over 10 years of investment banking, venture capital, marketing institutional trading and senior corporate management experience. Mr. Jia is familiar with all procedures for manufacturing and marketing with respect to the Asia pharmaceutical market, and has an in-depth understanding of the industry. Over the past few years, Mr. Jia has helped several Chinese domestic pharmaceutical companies list and obtain financing in the China stock exchange market (Shenzhen) and in Hong Kong. Prior to founding Jade Capital Group Ltd and Jade Pharmaceutical Inc., Mr. Jia served as Marketing Director for China Real Estate Corporation, one of the largest Chinese property corporations, between 1999 and 2003. Between 1989 and 1998, Mr. Jia served as General Manager of several branches of China Resource Co. Ltd (CRC), the largest China export and import corporation. From 1987 to 1989, Mr. Jia worked for the China National Machinery import and export corporation where he served as Manager of the Import Department for Medical Instruments. In addition to his business and entrepreneurial activities, Mr. Jia is a Senior Editor of China Finance. Mr. Jia is fluent in Mandarin, Cantonese, English and Vietnamese. Mr. Jia received his B.A. in economics from the University of International Business and Economics of China in 1987.

This document has been developed by Radient Pharmaceuticals Corporation. It is intended for informational purposes only. Neither the information, nor any opinion expressed, shall be construed to be an offer to sell or a solicitation of an offer to buy the securities mentioned herein.

SAFE HARBOR STATEMENT

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: The statements contained in this document include certain predictions and projections that may be considered forward- looking statements under securities law. These statements involve a number of important risks and uncertainties that could cause actual results to differ materially including, but not limited to, the performance of joint venture partners, as well as other economic, competitive and technological factors involving the Company's operations, markets, services, products, and prices. With respect to Radient Pharmaceuticals Inc., except for the historical information contained herein, the matters discussed in this document are forward looking statements involving risks and uncertainties that could cause actual results to differ materially from those in such forward-looking statements. There may be potential risks and uncertainties related to the Company's access to additional capital, competition and dependence on key management.